The FDA approved a new once-monthly subcutaneous injectable form of olanzapine for schizophrenia in adults. The drug, previously available in oral form, is now offered as a different formulation.
The FDA approved an oral drug for treating herpes lesions in immunocompromised patients who have not responded to other treatments. The drug is part of a new class of medications targeting herpes simplex virus.
The FDA approved atezolizumab for adjuvant treatment of stage III mismatch repair-deficient colon cancer. The approval is based on findings from a clinical trial involving patients aged two and older.
The FDA has approved a combination of atezolizumab and chemotherapy for treating colon cancer. This expands the list of tumor types for which atezolizumab is approved.
The FDA has approved a new size-adjustable pulmonary valve for children with congenital heart disease. The device may reduce the need for repeat surgeries as it grows with the patient.
The FDA has raised concerns after four deaths were reported in clinical trials involving an investigational drug for treatment-resistant schizophrenia. Newron Pharmaceuticals disclosed the findings.